Smith+Nephew partners with HOPCo to provide AI-powered analytics
and solutions to ASC customers
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology
company, today announces an exclusive digital and advanced
analytics collaboration with Healthcare Outcomes Performance
Company (HOPCo) – the world’s largest, fully-integrated,
musculoskeletal (MSK) value-based care and outcomes management
company. This collaboration will focus on enhancing solutions for
ASC customers, physicians, and their patients through HOPCo’s
digital health and analytics platforms,
myrecovery®
and Vitals®
The partnership with HOPCo provides a comprehensive technology
platform that encompasses all musculoskeletal procedures performed
in the ASC segment. The AI-powered myrecovery
platform enhances the clinical experience by utilizing patient
engagement tools such as remote care management, real time
communications, and remote therapeutic monitoring (RTM), while
providing critical* quality outcome metrics through proprietary
activity tracking technology, functional outcomes reporting,
patient-reported outcomes (PROMs), and longitudinal data
integration across a patient’s care journey. HOPCo’s
Vitals platform provides tools, analytics, and
dashboards to help Smith+Nephew customers deliver better, more
efficient and coordinated care while also meeting value-based care
requirements aiming to reduce cost.
"We are
thrilled to partner with HOPCo and the ability to bring their
innovative digital solutions to customers in the ASC across both
our Orthopaedic and Sports Medicine businesses. The HOPCo solutions
will allow our customers to unlock value in the ASC be it through
the use of RTM, PROMs, or leveraging analytics to drive
efficiencies. Their commitment to driving meaningful change in
outcomes through data aligns perfectly with the strength
and value of the CORI◊ Surgical System," said Craig
Gaffin, President of Global Orthopaedics at Smith+Nephew. "This
collaboration underscores our commitment to advancing orthopaedic
surgery through innovative technology, improving patient outcomes,
and transforming the future of healthcare."
Data from the CORI Surgical System’s ability to perform
image-agnostic robotic-assisted knee surgeries will now be
augmented with the powerful data-driven insights from HOPCo’s
Vitals and AI-powered myrecovery
digital solutions. The integrated digital platform will encompass
some of the most advanced practice and health system analytics
solutions available. Planned integration with Smith+Nephew’s
intraoperative data from the CORI Surgical System through
RI.INSIGHTS Data Visualization Platform will provide surgeons and
healthcare providers with enhanced analytics to link personalized
surgical planning, intra-operative decision-making, and PROMS
tracking and optimization.
“Smith+Nephew is clearly committed to using outcomes data to
enhance the value of its products and services,” said Dr. David
Jacofsky, CEO and Chairman at HOPCo. “HOPCo’s
myrecovery and Vitals platforms
will allow Smith+Nephew to leverage unique longitudinal data to do
just that, while simultaneously providing meaningful additional
value to customers and improving patient outcomes.”
- ends –
* https://www.federalregister.gov/documents/2023/11/22/2023-24293/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment
Media Enquiries
Dave Snyder +1
(978) 749-1440
Smith+Nephew
david.snyder@smith-nephew.com
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people’s bodies and their self-belief
by using technology to take the limits off living. We call this
purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission
every day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
business units of Orthopaedics, Sports Medicine & ENT and
Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.5 billion in 2023.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on X, LinkedIn, Instagram
or Facebook.
About HOPCo
Healthcare Outcomes Performance Company (HOPCo) is the global
leader of integrated musculoskeletal value-based health outcomes
management, digital analytics, practice management, and health
system service line management. This includes comprehensive
expertise across all MSK specialties, including orthopedics, spine,
pain management, rehabilitation, neurosurgery, and neurology.
HOPCo's integrated care, analytics, and facilities development
platforms have proven to increase the quality of patient care while
reliably reducing the total cost of MSK care across the care
continuum for practices, health systems and payors alike. HOPCo's
affiliated payors, practices and health systems successfully
participate in highly efficient value-based contracting (bundled
payments, population health programs, and other advanced risk-based
arrangements) utilizing HOPCo's proprietary platforms, IT
solutions, integrated analytics, advanced medical economics and
standardized care pathways. Visit www.hopco.com to learn
more.
Forward-looking Statements
This document may contain forward-looking statements that
may or may not prove accurate. For example, statements regarding
expected revenue growth and trading profit margins, market trends
and our product pipeline are forward-looking statements. Phrases
such as "aim", "plan", "intend", "anticipate", "well-placed",
"believe", "estimate", "expect", "target", "consider" and similar
expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown
risks, uncertainties and other important factors that could cause
actual results to differ materially from what is expressed or
implied by the statements. For Smith+Nephew, these factors include:
conflicts in Europe and the Middle East, economic and financial
conditions in the markets we serve, especially those affecting
healthcare providers, payers and customers; price levels for
established and innovative medical devices; developments in medical
technology; regulatory approvals, reimbursement decisions or other
government actions; product defects or recalls or other problems
with quality management systems or failure to comply with related
regulations; litigation relating to patent or other claims; legal
and financial compliance risks and related investigative, remedial
or enforcement actions; disruption to our supply chain or
operations or those of our suppliers; competition for qualified
personnel; strategic actions, including acquisitions and disposals,
our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions
or other changes we make in our business plans or organisation to
adapt to market developments; relationships with healthcare
professionals; reliance on information technology and
cybersecurity; disruptions due to natural disasters, weather and
climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation
regulations; effects of foreign exchange volatility; and numerous
other matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with the
U.S. Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith+Nephew's most
recent annual report on Form 20-F, which is available on the SEC’s
website at www. sec.gov, for a discussion of certain of these
factors. Any forward-looking statement is based on information
available to Smith+Nephew as of the date of the statement. All
written or oral forward-looking statements attributable to
Smith+Nephew are qualified by this caution. Smith+Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in
Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain
marks registered in US Patent and Trademark Office.
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Smith & Nephew (LSE:SN.)
Storico
Da Dic 2023 a Dic 2024